ACE2 and lung carcinoma: There was no statistically significant difference in ACE2 expression according to age > 65, male sex, overweight, COPD, lung cancer, cardiovascular disease (CVD), diabetes mellitus (DM), or use of renin–angiotensin–aldosterone system (RAAS) inhibitors.